Showing results (21-30 of 322) with videos related to
Sort By:
Pageof 33
American Journal of Hematology|February 24, 2024
Risk models in myelofibrosis-the past, present, and futureAyalew Tefferi, Alessandro M VannucchiF1000 Medicine Reports|October 16, 2010
Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasmsPaola Guglielmelli, Alessandro M VannucchiHaematologica|January 2, 2008
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemiaElisabetta Antonioli, Paola Guglielmelli, Giada Poli, et al.International Journal of Hematology|March 30, 2022
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectivesGiuseppe G Loscocco, Alessandro M VannucchiBlood|December 29, 2016
Emerging treatments for classical myeloproliferative neoplasmsAlessandro M Vannucchi, Claire N HarrisonExpert Opinion on Pharmacotherapy|April 5, 2011
Therapeutic approaches in myelofibrosisGiovanni Barosi, Vittorio Rosti, Alessandro M VannucchiCurrent Hematologic Malignancy Reports|October 23, 2013
Preclinical models for drug selection in myeloproliferative neoplasmsNiccolò Bartalucci, Costanza Bogani, Alessandro M VannucchiCurrent Opinion in Hematology|December 2, 2017
Polycythemia vera and essential thrombocythemia: algorithmic approachAlessandro M Vannucchi, Paola Guglielmelli, Ayalew TefferiExpert Opinion on Drug Safety|December 29, 2023
A safety evaluation of ruxolitinib for the treatment of polycythemia veraValentina Boldrini, Alessandro M Vannucchi, Paola GuglielmelliBlood Cancer Journal|January 12, 2018
Essential thrombocythemia treatment algorithm 2018Ayalew Tefferi, Alessandro M Vannucchi, Tiziano BarbuiPageof 33